Moreover, Amabile et al. [94] showed that 5-azacytidine significantly decreases the malignant potential of BCR-ABL+ cells in a mouse model of CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.